| Autor: |
van Moorsel SA; Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Sittard-Geleen;†Department of Pediatrics, Zuyderland Medical Centre, Heerlen; and‡Department of Clinical Pharmacy and Toxicology, Zuyderland Medical Centre, Heerlen, the Netherlands., Bevers N, Meurs M, van Rossum LK, Hooymans PM, Wong DR |
| Jazyk: |
angličtina |
| Zdroj: |
Therapeutic drug monitoring [Ther Drug Monit] 2017 Feb; Vol. 39 (1), pp. 1-4. |
| DOI: |
10.1097/FTD.0000000000000366 |
| Abstrakt: |
We describe the case of a pediatric patient on azathioprine therapy with previously undiagnosed homozygote thiopurine S-methyltransferase (TPMT) deficiency, resulting in myelotoxic thiopurine metabolite levels. The patient was successfully treated with a very low azathioprine dose of 50 mg once a week (4% of standard dose), guided by frequent thiopurine metabolite measurement and a close clinical surveillance. We demonstrate that azathioprine therapy still might be an effective and safe therapeutic option in pediatric thiopurine S-methyltransferase-deficient IBD patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
